Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Y-Mabs Therapeutics (YMAB – Research Report). The associated price ...

Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on YMAB stock, giving a Buy rating on December 4.Pick the best ...

Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...

Fintel reports that on December 5, 2024, Brookline Capital initiated coverage of Y-mAbs Therapeutics (NasdaqGS:YMAB) with a ...

Across the recent three months, 5 analysts have shared their insights on Y-mAbs Therapeutics (NASDAQ:YMAB), expressing a variety of opinions spanning from bullish to bearish. The following table ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company valued at $460 million, has garnered attention from analysts for its innovative approach to cancer treatment ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company valued at $460 million, has garnered attention from analysts for its innovative approach to cancer treatment, ...

Fintel reports that on December 5, 2024, Brookline Capital initiated coverage of Y-mAbs Therapeutics (NasdaqGS:YMAB) with a Buy recommendation. As of December 3, 2024, the average one-year price ...

If you want to know who really controls Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in ...